Compare 10X Genomics Inc (TXG) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Weibo Corp — how do they compare? 10X Genomics Inc trades at $81.19 (market cap $10.07B), while Weibo Corp trades at $6.53 (market cap $1.56B). The key difference: 10X Genomics Inc is far larger — about 6.5× Weibo Corp's market cap, and Weibo Corp pays a 9.47% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Weibo Corp for 102 Days on average.
| TXG | WB | |
|---|---|---|
Market Cap | $10.07B | $1.56B |
Volume | 5,657,286 | 812,503 |
Sector | Health | Media |
52-Week High | $97.74 | $12.37 |
52-Week Low | $11.48 | $6.33 |
Typical Hold Time | 91 Days | 102 Days |
Enterprise Value | $9.59B | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Weibo (WB) trades at $6.55, up 1.08% with bearish technical indicators but attractive valuation metrics including a P/E of 5.32 and P/B of 0.4. The company reported Q2 2026 earnings beat with $449M net income in 2025, though recent quarters show mixed results. Cash flow trends show volatility with a $694M net outflow in 2024, while analyst sentiment remains divided with 40.9% buy ratings amid concerns about user growth stagnation.
WB presents as a deep-value opportunity with strong profitability margins but faces significant headwinds from declining user metrics and advertising challenges. The stock's low valuation multiples suggest potential upside if operational stability improves, though competitive pressures and China's regulatory environment remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
